Trial Profile

Phase I Clinical Study of Safety Tolerability Pharmacokinetics and Pharmacodynamics of Recombinant Humanized Cytotoxic T Lymphocyte Antigen 4 Single Domain Antibody Fc Fusion Protein Injection in Subjects With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KN 044 (Primary)
Indications Advanced breast cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Prostate cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions
Sponsors Changchun Intellicrown Pharmaceutical

30 Aug 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
30 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
31 Jan 2023 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com